Education
About Us
Working with TipRanks
Follow Us
Panbela Therapeutics, Inc. (PBLA)
:PBLA
Top Page
Panbela Therapeutics
(OTC:PBLA)
37Underperform
Panbela Therapeutics (PBLA) vs. S&P 500 (SPY)
Market Cap
$1.89M
Dividend YieldN/A
Average Volume (3M)22.64K
Price to Earnings (P/E)―
Beta (1Y)-0.18
Revenue GrowthN/A
EPS Growth99.19%
CountryUS
Employees8
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-32.52
Shares Outstanding4,854,831
10 Day Avg. Volume22,897
30 Day Avg. Volume22,635
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Panbela Therapeutics Business Overview & Revenue Model
Company DescriptionSun BioPharma Inc. is a clinical-stage drug development company, which engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The company was founded by Michael Cullen and Thomas Neenan on September 21, 2011 and is headquartered in Waconia, MN.
How the Company Makes MoneyPanbela Therapeutics generates revenue primarily through the development and commercialization of its proprietary cancer therapies. The company invests heavily in research and development to bring its innovations from the lab to the market. Potential revenue streams include licensing agreements with larger pharmaceutical companies, milestone payments based on the achievement of clinical and regulatory benchmarks, and future sales of approved therapies. Panbela may also receive funding through strategic partnerships, grants, and potential collaborations with academic and research institutions dedicated to cancer treatment advancements. As these therapies progress through clinical trials and regulatory approvals, Panbela aims to establish a robust market presence and generate significant revenue from the commercial distribution of its products.
Panbela Therapeutics Financial Statement Overview
Summary
Panbela Therapeutics is facing significant financial challenges with no revenue and consistent losses, leading to negative equity and a reliance on financing for cash flow. The biotechnology industry often requires substantial investment before profitability; however, the current trajectory highlights significant financial instability and risk.Income Statement
Panbela Therapeutics has consistently reported negative gross profit, EBIT, and net income over the past several years, with no revenue generated. This indicates a challenging financial position with high operational costs and no income to offset these expenses. The company lacks revenue growth, which is crucial for financial improvement.10
Very Negative
Balance Sheet
The company's balance sheet shows negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, posing a risk of insolvency. The equity ratio is also negative, reflecting weak financial stability.15
Very Negative
Cash Flow
Panbela Therapeutics has negative free cash flow, suggesting it is not generating enough cash to sustain operations and relies heavily on financing activities. However, the company has maintained some cash flow through financing, which indicates a potential to manage short-term liquidity needs.20
Very Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -29.04M | -25.65M | -35.73M | -10.01M | -5.75M | -4.32M | EBIT |
| -36.20M | -51.29M | -34.09M | -10.01M | -5.75M | -4.32M | EBITDA |
| -27.43M | -51.29M | -34.76M | -10.61M | -5.15M | -4.42M | Net Income Common Stockholders |
| -27.91M | -25.26M | -34.93M | -10.13M | -4.77M | -6.20M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 262.00K | 2.58M | 1.28M | 11.87M | 9.02M | 2.45M | Total Assets |
| 10.53M | 11.80M | 4.98M | 12.87M | 9.81M | 3.14M | Total Debt |
| 4.19M | 5.19M | 6.84M | 0.00 | 0.00 | 116.00K | Net Debt |
| 3.93M | 2.62M | 5.56M | -11.87M | -9.02M | -2.33M | Total Liabilities |
| 13.71M | 16.51M | 13.03M | 2.66M | 1.36M | 1.76M | Stockholders Equity |
| -3.19M | -4.71M | -8.05M | 10.21M | 8.45M | 1.39M |
| Cash Flow | Free Cash Flow | ||||
| -15.57M | -25.25M | -15.94M | -6.70M | -3.85M | -2.74M | Operating Cash Flow |
| -15.57M | -25.25M | -15.28M | -6.70M | -3.85M | -2.74M | Investing Cash Flow |
| -7.97M | 400.00K | -656.00K | -540.00K | 0.00 | 0.00 | Financing Cash Flow |
| 14.03M | 26.14M | 5.35M | 10.10M | 10.44M | 3.78M |
Panbela Therapeutics Technical Analysis
Positive
0.39
Price Trends
0.37
Positive
0.35
Positive
0.36
Positive
Market Momentum
<0.01
Negative
55.48
Neutral
64.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBLA, the sentiment is Positive. The current price of 0.39 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.37, and above the 200-day MA of 0.36, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.48 is Neutral, neither overbought nor oversold. The STOCH value of 64.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBLA.
Panbela Therapeutics Risk Analysis
Panbela Therapeutics disclosed 34 risk factors in its most recent earnings report. Panbela Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Panbela Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $10.69B | 33.14 | 14.16% | ― | 24.81% | 33.67% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
42 Neutral | $110.00M | ― | -54.21% | ― | -78.55% | -0.92% | |
40 Underperform | $28.41M | ― | -136.05% | ― | -42.92% | 26.30% | |
37 Underperform | $1.89M | ― | 153.59% | ― | ― | 99.19% |
* Healthcare Sector Average
Performance Comparison
PBLA
Panbela Therapeutics
0.40
-0.20
-33.33%
CASI
CASI Pharmaceuticals
2.07
-1.42
-40.69%
NBIX
Neurocrine
108.99
-30.17
-21.68%
FATE
Fate Therapeutics
0.94
-6.29
-87.00%
Panbela Therapeutics Earnings Call Summary
Earnings Call Date: Nov 14, 2024 | % Change Since: 30.00% | Next Earnings Date: Mar 20, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments in clinical trials and strategic investments, balanced by financial challenges and cash flow concerns. The strategic investment from Nant Capital and progress in clinical trials were notable positives, but the financial challenges indicate ongoing risks.Highlights
Strategic Investment from Nant Capital
A $12 million strategic loan commitment from Nant Capital, consisting of two tranches of convertible promissory notes, demonstrating confidence in Panbela's multi-targeted approach to pancreatic cancer treatment.
ASPIRE Trial Progress
The Phase III ASPIRE global clinical trial for metastatic pancreatic ductal adenocarcinoma is showing a notably lower event rate, potentially signaling better patient outcomes and a significant advance over current standards of care.
Eflornithine FDA Approval
Eflornithine received FDA approval, marking the first FDA-approved polyamine-targeted therapy in cancer, validating Panbela's polyamine-focused approach.
Advancements in Clinical Pipeline
Progress in Phase II and Phase I trials, including the eflornithine study in prostate cancer and the initiation of a study for STK11 mutant non-small cell lung cancer.
Lowlights
Financial Challenges
Net loss of $7.2 million for Q3 2024 with total current assets at $5.2 million and current liabilities at $20.1 million, indicating financial strain despite recent funding.
Cash Flow Concerns
Total cash as of September 30, 2024, was approximately $142,000, reflecting the company's reliance on new funding arrangements to manage operations.
Company Guidance
During the Panbela Therapeutics Q3 2024 earnings call, the company provided several key guidance metrics. Jennifer Simpson, the CEO, highlighted a $12 million strategic loan commitment from Nant Capital, with $2.85 million already funded and an additional $9.15 million expected by November 15. The company is advancing its Phase III ASPIRE global clinical trial, targeting full enrollment of approximately 600 patients by Q2 2025, and anticipates an interim analysis in Q1 2025. Additionally, general and administrative expenses were stable at $1.1 million, while research and development expenses decreased slightly to $6.1 million from the prior year. The net loss for the quarter was $7.2 million, with cash reserves at about $142,000 as of September 30, not reflecting the recent funding. The guidance emphasized the strategic importance of ongoing clinical developments and the financial backing to support future advancements.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.